The AMR Action Fund, a public-private partnership investing in biotech companies developing antimicrobials, has invested in BioVersys AG, a clinical-stage company based in Basel, Switzerland. The transaction marks the Fund’s first investment in Europe and is an important step toward building an international portfolio of companies that are developing urgently needed antimicrobials. Drug-resistant bacterial infections […]

The post The AMR Action Fund Invests in BioVersys in Fight Against Drug-Resistant Bacteria first appeared on World Pharma Today.